Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD · NASDAQ Global Select
+$0.09 today
Vol 0.14M · Avg 0.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-54.0%
avg 13.2%
ROIC
-58.6%
avg -59.9%
ROA
-49.1%
avg -56.3%
Analysis
ROA is currently the strongest return metric at -49.1% versus its period average of -56.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Tien-Li Lee | Chief Executive Officer, Secretary & Director | $973,658.00 | — | 51 | $203,851.00 | 0.93% |
Manasi Sinha Jaiman | Chief Medical Officer | $693,039.00 | — | 45 | $70,549.00 | 0.32% |
Nelson Sun | CFO & COO | $603,300.00 | — | 49 | $70,549.00 | 0.32% |
Ron Lewis | Vice President & Head of CMC | — | — | — | — | — |
Timothy J. Kieffer | Chief Scientific Officer | — | — | 59 | — | — |
Zhenhuan Zheng | Chief Research Officer | — | — | — | — | — |
Danny Villeneuve | Chief Commercial Officer | — | — | — | — | — |
Justin T. Stege | VP and Head of Project Management & Strategy | — | — | — | — | — |
Derrick C. Li | Chief Business Officer | — | — | — | — | — |
Dvorit Samid | Executive Vice President of Medical Affairs | — | — | — | — | — |
Terrie Kellmeyer | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Christian Zapf | General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
8
$450,312.40
Sells
0
$0.00
Net Sentiment
+$450,312.40
Net buying
Most Active
Lee Tien-Li
6 transactions
Analysis
Insiders reported 8 buys worth $450,312.40 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $450,312.40. Lee Tien-Li was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$391.88M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$294.85M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$278.94M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$243.08M
Zura Bio Limited
NASDAQ:ZURA
$240.96M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$210.92M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$170.65M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$161.66M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$127.03M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$117.86M
Who manages AARD?
Aardvark Therapeutics, Inc. Common Stock (AARD) lists 12 active executives. The top listed executive is Nelson Sun, CFO & COO.
Are AARD insiders buying or selling?
Recent insider activity shows net buying of $9.56M.
Explore More
Continue the stock analysis
Jump to another research area for this company.